Dynamic Digital Twins for Adaptive Cancer Management: From Predictive Modeling to Personalized Therapy

[1]Dr. Abhinav Sen,[2]Dr. Neha Kulshreshtha,[3]Dr. Rajesh Naidu,[4]Mrs. Swati Verma

[1]Professor,Department of Cardiology, Vydehi Institute of Medical Sciences, Bengaluru, India.

Abhinavsen81@gmail.com

[2]Associate Professor,Department of Pharmacology, Vydehi Institute of Medical Sciences, Bengaluru, India.Nehakulshreshtha34@gmail.com

[3]Assistant Professor,Department of Pathology, Vydehi Institute of Medical Sciences, Bengaluru, India.Rajeshnaidu55@gmail.com

[4]Assistant Professor,Department of Anatomy, Vydehi Institute of Medical Sciences, Bengaluru, India.Swativerma93@gmail.com

ABSTRACT:

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. The biological complexity of cancer, together with continuous changes in tumor evolution, immune interactions, and therapeutic response, necessitates computational approaches capable of adapting alongside the patient's disease. Dynamic digital twins have emerged as a transformative paradigm in precision oncology by creating continuously evolving virtual representations of individual patients that integrate radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical data. Unlike conventional predictive models based on static datasets, dynamic digital twins continuously update their computational state as new patient information becomes available, enabling adaptive prediction of disease progression, therapeutic response, treatment-related toxicity, recurrence, and long-term clinical outcomes. Advances in artificial intelligence (AI), multimodal foundation models, transformer architectures, graph neural networks, reinforcement learning, agentic AI, digital health technologies, and cloud computing have significantly accelerated development of dynamic digital twin ecosystems capable of supporting diagnosis, prognostic prediction, treatment optimization, adaptive radiation therapy, immunotherapy, surgical planning, drug discovery, and clinical decision support. Despite remarkable technological progress, challenges remain regarding interoperability, computational scalability, explainability, cybersecurity, regulatory validation, and ethical governance. This review provides a comprehensive overview of dynamic digital twins in adaptive cancer management, highlighting computational foundations, current clinical applications, implementation challenges, and future perspectives for personalized oncology.[1]

Keywords: Digital twins, Adaptive oncology, Artificial intelligence, Precision medicine, Computational oncology, Personalized therapy, Machine learning, Clinical decision support, Dynamic modeling, Digital health.

Received Date: 5 December 2025; **Accepted Date:** 15 December 2025; **Published Date:** 20 December 2025.

1.Introduction

Cancer is a biologically dynamic disease characterized by genomic instability, epigenetic alterations, immune heterogeneity, metabolic reprogramming, and continuous interactions between malignant cells and the surrounding tumor microenvironment. Although advances in molecular medicine and targeted therapies have significantly improved patient outcomes, tumors continue to evolve throughout treatment, resulting in therapeutic resistance, disease progression, and variable clinical outcomes among patients with apparently similar diagnoses.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, and electronic health records. These multimodal datasets provide increasingly comprehensive insight into tumor biology; however, conventional computational approaches frequently analyze them as static information rather than continuously evolving biological systems.[3]

Artificial intelligence has emerged as one of the most influential technologies in computational oncology by enabling automated interpretation of complex biomedical information. More recently, dynamic digital twins have extended these capabilities by continuously synchronizing virtual computational models with biological patients throughout diagnosis, treatment, follow-up, and survivorship.[4]

By integrating multimodal biomedical information into adaptive virtual patient models, dynamic digital twins enable predictive modeling, individualized therapeutic optimization, continuous disease monitoring, and real-time clinical intelligence that collectively support next-generation precision oncology.[5]

2.Evolution of Digital Twins in Oncology

Digital twin technology originated within engineering and manufacturing, where virtual replicas of complex physical systems were developed to monitor operational performance, predict failures, and optimize maintenance. These computational principles were subsequently adapted to healthcare, enabling simulation of physiological processes, disease progression, and therapeutic interventions using patient-specific virtual models.[6]

Early healthcare digital twins primarily focused on cardiovascular disease, diabetes, orthopedic biomechanics, and critical care medicine. Oncology rapidly emerged as one of the most promising clinical applications because cancer management requires continuous integration of radiological imaging, pathology, molecular biology, genomics, laboratory investigations, and longitudinal patient monitoring.

Recent advances in artificial intelligence, multimodal learning, cloud computing, digital health technologies, wearable biosensors, and electronic health records have transformed traditional digital twins into dynamic computational ecosystems capable of continuously learning from evolving patient information.[7]

Dynamic digital twins therefore represent the next evolution of precision oncology by enabling adaptive computational reasoning throughout the entire cancer care continuum.

3.Computational Principles of Dynamic Digital Twins

Dynamic digital twins differ fundamentally from conventional predictive models because they continuously synchronize computational representations with evolving biological systems rather than relying on static baseline datasets. Artificial intelligence enables these virtual patient models to update automatically whenever new biomedical information becomes available.[8]

The computational framework integrates multimodal biomedical data including radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, physiological monitoring, medication history, wearable devices, and electronic health records into unified patient-specific computational representations.

Machine learning, deep learning, transformer architectures, graph neural networks, reinforcement learning, and multimodal foundation models collectively support predictive reasoning regarding tumor evolution, therapeutic response, recurrence, toxicity, and long-term disease progression.

Continuous feedback loops enable dynamic digital twins to evolve alongside changing patient biology, thereby supporting adaptive precision medicine rather than static prediction.[9]

4.Computational Architecture

Dynamic digital twin ecosystems consist of several interconnected computational layers responsible for multimodal data acquisition, preprocessing, representation learning, simulation, continuous synchronization, predictive modeling, and intelligent clinical decision support.[10]

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.13

The acquisition layer collects radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable sensor data, medication history, physiological monitoring, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives through natural language processing, and synchronize temporal clinical information.

Large transformer architectures and multimodal foundation models subsequently generate generalized computational embeddings representing patient-specific biological states. Mathematical simulation engines model tumor growth, metastatic dissemination, immune interactions, therapeutic interventions, toxicity, recurrence, and disease progression.

Continuous synchronization with newly acquired patient information enables adaptive updating of virtual patient models throughout diagnosis, treatment, follow-up, and survivorship.[11]

5.Artificial Intelligence as the Computational Engine

Artificial intelligence forms the computational foundation of dynamic digital twins by enabling continuous interpretation of heterogeneous biomedical information. Machine learning algorithms identify statistical relationships among clinical variables and patient outcomes, supporting prediction of recurrence, survival, treatment response, and toxicity across diverse malignancies.[12]

Deep learning substantially enhances predictive capability through automated extraction of hierarchical features from radiological imaging, digital pathology, molecular biology, physiological monitoring, and wearable technologies. Transformer architectures efficiently integrate multimodal biomedical information while graph neural networks model biological interaction networks involving genes, proteins, signaling pathways, immune responses, and therapeutic targets.

Foundation models further strengthen scalability through generalized biomedical representation learning that can subsequently be adapted across numerous oncology applications, improving robustness while reducing dependence on manually annotated datasets.[13]

6.Multimodal Biomedical Integration

The effectiveness of dynamic digital twins depends upon seamless integration of heterogeneous biomedical information into unified computational representations. Cancer biology cannot be adequately represented using individual biomarkers because disease behavior reflects interactions among imaging, pathology, molecular biology, physiology, environmental influences, and longitudinal clinical events.[14]

Radiological imaging contributes anatomical and functional information regarding tumor morphology, vascularity, metabolism, and disease progression. Digital pathology provides microscopic characterization of tissue architecture, cellular differentiation, stromal remodeling, angiogenesis, immune infiltration, and tumor heterogeneity.

Genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, and electronic health records provide complementary molecular and physiological information describing evolving patient trajectories.

Artificial intelligence harmonizes these multimodal datasets into continuously evolving patient-specific computational representations supporting adaptive precision oncology.[15]

7.Predictive Modeling of Cancer Progression

One of the defining capabilities of dynamic digital twins is predictive modeling of disease evolution through continuous simulation of patient-specific biological processes. Rather than producing isolated risk estimates, dynamic digital twins generate continuously updated computational trajectories describing tumor growth, metastatic dissemination, therapeutic response, recurrence, toxicity, and survival.[16]

Artificial intelligence integrates imaging findings, molecular biomarkers, pathology, laboratory investigations, wearable sensor data, and longitudinal clinical information to anticipate future clinical events before they become clinically apparent.

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.13

These predictive simulations enable clinicians to identify emerging therapeutic resistance, optimize treatment timing, anticipate complications, and proactively intervene before significant disease progression occurs, thereby improving individualized patient management.[17]

8.Dynamic Digital Twins in Cancer Diagnosis

Accurate diagnosis remains the foundation of effective oncology care, and dynamic digital twins significantly improve diagnostic precision by integrating imaging, pathology, genomics, laboratory biomarkers, and clinical documentation into adaptive computational frameworks.[18]

Deep learning algorithms automatically detect tumors across computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and digital pathology while multimodal reasoning systems combine these findings with molecular biology and longitudinal patient history.

Continuous synchronization allows diagnostic models to update as new imaging studies, pathological assessments, molecular analyses, and laboratory investigations become available, enabling increasingly accurate disease classification, molecular characterization, staging, and individualized patient assessment throughout the cancer journey.[19]

9.Adaptive Personalized Therapy Through Dynamic Digital Twins

One of the greatest clinical advantages of dynamic digital twins is their ability to support adaptive personalized therapy by continuously evaluating changes in tumor biology throughout treatment. Unlike conventional therapeutic planning based primarily on baseline clinical information, dynamic digital twins integrate sequential imaging studies, digital pathology, molecular biomarkers, laboratory investigations, wearable sensor data, treatment history, and longitudinal clinical outcomes into continuously evolving computational models.[20]

Artificial intelligence estimates treatment response, recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance across chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations.

Because digital twins continuously synchronize with newly acquired patient information, therapeutic recommendations evolve throughout treatment, enabling clinicians to modify interventions according to the changing biological characteristics of both the tumor and the patient.

10.Dynamic Digital Twins in Immunotherapy

The tumor immune microenvironment continuously changes during cancer progression and therapeutic intervention, making immunotherapy prediction particularly challenging. Dynamic digital twins address this complexity by integrating radiological imaging, digital pathology, transcriptomics, immunomics, laboratory biomarkers, wearable technologies, and longitudinal clinical outcomes into adaptive computational immune models.[21]

Artificial intelligence evaluates tumor-infiltrating lymphocytes, immune checkpoint expression, cytokine signaling pathways, stromal remodeling, angiogenesis, immune-cell spatial organization, and treatment-related immune responses while continuously updating virtual patient models.

These adaptive computational simulations enable prediction of responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies while supporting increasingly individualized immunotherapeutic strategies.

11.Adaptive Radiation Oncology and Surgical Planning

Radiation oncology and surgical oncology both benefit substantially from continuous computational adaptation provided by dynamic digital twins. Sequential imaging obtained during radiation therapy enables artificial intelligence to update tumor contours, estimate radiation sensitivity, evaluate anatomical changes, and optimize dose distribution throughout treatment.[22]

Adaptive radiation planning improves tumor targeting while minimizing unnecessary radiation exposure to surrounding healthy tissues, thereby

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.13

enhancing therapeutic effectiveness and reducing treatment-related toxicity.

Within surgical oncology, dynamic digital twins generate three-dimensional patient-specific anatomical models integrating imaging, pathology, vascular anatomy, molecular biology, and physiological information. Artificial intelligence predicts surgical complexity, estimates resection margins, evaluates postoperative complications, and continuously updates operative planning as new clinical information becomes available.

12.Drug Discovery and Intelligent Clinical Decision Support

Dynamic digital twins extend beyond patient management into oncology drug discovery and clinical decision support. Artificial intelligence integrates systems pharmacology, molecular biology, imaging, pathology, genomics, laboratory investigations, and longitudinal patient trajectories to simulate therapeutic efficacy, toxicity, pharmacokinetics, pharmacodynamics, and resistance mechanisms before clinical implementation.[23]

Generative artificial intelligence further strengthens pharmaceutical research by designing candidate molecules, predicting drug-target interactions, modeling biological responses, and generating synthetic biomedical datasets that accelerate translational oncology.

Within routine clinical practice, dynamic digital twin ecosystems provide interactive decision-support platforms integrating multimodal biomedical information into individualized diagnostic summaries, therapeutic recommendations, toxicity estimates, recurrence predictions, survival probabilities, and adaptive clinical pathways while maintaining physician oversight.

13.Explainable Artificial Intelligence and Trustworthy Dynamic Systems

Clinical implementation of dynamic digital twins depends upon transparency, interpretability, and clinician confidence. Explainable artificial intelligence (XAI) enables healthcare professionals to understand how continuously evolving computational models generate predictions through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual reasoning.[24]

Transparent explanations identify biological variables contributing to diagnostic predictions, therapeutic recommendations, toxicity estimates, and disease simulations, thereby facilitating multidisciplinary interpretation while strengthening clinician trust.

As adaptive computational systems become increasingly autonomous, explainability will remain essential for ensuring accountability, patient safety, regulatory compliance, and responsible implementation within routine precision oncology.

14.Challenges, Ethics, and Future Directions

Despite remarkable technological progress, dynamic digital twins remain associated with important computational, technical, ethical, and regulatory challenges. Continuous synchronization requires standardized multimodal datasets, high-performance computational infrastructure, secure cloud computing, interoperability among healthcare systems, and reliable integration of heterogeneous biomedical information.[25]

Additional concerns include algorithmic bias, cybersecurity, patient privacy, informed consent, data ownership, regulatory approval, medico-legal accountability, and equitable access to advanced computational healthcare technologies. Addressing these challenges will require transparent governance frameworks, standardized validation methodologies, secure digital infrastructure, federated learning, and international collaboration among clinicians, engineers, computer scientists, regulators, and healthcare organizations.

Future developments involving multimodal foundation models, agentic artificial intelligence, reinforcement learning, quantum computing, liquid biopsy, spatial multi-omics, wearable biosensors, cloud-native healthcare infrastructure, and Internet of Medical Things (IoMT) technologies are expected to substantially strengthen adaptive digital twin ecosystems.

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.13

15.Discussion

Dynamic digital twins represent one of the most important paradigm shifts in computational oncology by transforming conventional predictive models into continuously evolving computational ecosystems synchronized with individual patients throughout diagnosis, treatment, follow-up, and survivorship.[26]

Unlike static predictive algorithms, dynamic digital twins continuously integrate radiological imaging, digital pathology, molecular biology, laboratory investigations, wearable technologies, and longitudinal clinical information to support adaptive therapeutic optimization, predictive disease modeling, intelligent clinical decision support, and personalized cancer care.

Applications spanning diagnosis, therapeutic planning, immunotherapy, radiation oncology, surgical planning, drug discovery, digital health, and survivorship management demonstrate the extraordinary clinical potential of adaptive computational oncology while highlighting the need for prospective validation and multidisciplinary collaboration.

16.Conclusion

Dynamic digital twins are redefining adaptive cancer management by enabling continuously evolving virtual patient models that integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical information into intelligent computational ecosystems.[27]

Artificial intelligence continuously synchronizes these virtual patients with evolving biological systems, enabling predictive disease modeling, adaptive therapeutic optimization, continuous treatment monitoring, toxicity prediction, and evidence-based clinical decision-making throughout the entire oncology workflow.[28]

As multimodal foundation models, agentic artificial intelligence, federated learning, reinforcement learning, digital health technologies, cloud computing, and computational systems biology continue to mature, dynamic digital twins are expected to become fundamental components of next-generation precision oncology. Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible implementation of adaptive digital twin ecosystems, ultimately improving patient outcomes and advancing the future of personalized cancer medicine worldwide.[29][30]

17.References

1.Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

3.Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.

4.Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.

5.Dr.Ohmini Krishnamurthy Rajendran (Author), ANALYSIS OF DNA-DAMAGE AND CANCER-RELATED GENE EXPRESSION FOLLOWING SPACE-RADIATION EXPOSURE USING NASA OPEN SCIENCE DATA, Vol. 11 No. 5s (2025), International Journal of Advances in Signal and Image Sciences (IJASIS), https://xlescience.org/index.php/IJASIS/article/view/2054, DOI: https://doi.org/10.29284/jqgs5s28

6.Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.

7.Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.

8.Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

9.Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial, Nature, 616(7956), pp. 259-265.

10.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

11.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

12.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

13.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

14.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

15.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

16.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

17.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

18.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

19.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

20.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

21.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

22.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

23.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

24.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

25.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

26.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL Intelligence'DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

27.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

28.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

29.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

30.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8